<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">psychiatry</journal-id><journal-title-group><journal-title xml:lang="ru">ПСИХИАТРИЯ</journal-title><trans-title-group xml:lang="en"><trans-title>Psychiatry (Moscow) (Psikhiatriya)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-8319</issn><issn pub-type="epub">2618-6667</issn><publisher><publisher-name>FSBSI “The Mental Health Research Centre”;   LLC «Publisher «MIA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2618-6667-2024-22-5-29-37</article-id><article-id custom-type="elpub" pub-id-type="custom">psychiatry-1246</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПСИХОПАТОЛОГИЯ, КЛИНИЧЕСКАЯ И БИОЛОГИЧЕСКАЯ ПСИХИАТРИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PSYCHOPATHOLOGY, CLINICAL AND BIOLOGICAL PSYCHIATRY</subject></subj-group></article-categories><title-group><article-title>Активность тромбоцитарных и эритроцитарных ферментов метаболизма глутатиона у больных с расстройствами шизофренического спектра с периодической кататонией</article-title><trans-title-group xml:lang="en"><trans-title>Activity of Platelet and Erythrocyte Enzymes of Glutathione Metabolism in Patients with Schizophrenia Spectrum Disorders with Periodic Catatonia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5996-6606</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савушкина</surname><given-names>О. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Savushkina</surname><given-names>O. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Константиновна Савушкина, кандидат биологических наук, исполняющий обязанности заведующего лабораторией, ведущий научный сотрудник, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Olga K. Savushkina, Cand. Sci. (Biol.), Acting Head of Laboratory, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">osavushkina1@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1369-8658</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бокша</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Boksha</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Сергеевна Бокша, доктор биологических наук, главный научный сотрудник, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Irina S. Boksha, Dr. Sci. (Biol.), Chief Researcher, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">boksha_irina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3574-2165</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прохорова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Prokhorova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Андреевна Прохорова, научный сотрудник, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatyana A. Prokhorova, Researcher, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">gnidra@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4784-8995</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терешкина</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Tereshkina</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Борисовна Терешкина, кандидат биологических наук, старший научный сотрудник, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Elena B. Tereshkina, Cand. Sci. (Biol.), Senior researcher, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">tereshkina.el@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5766-0910</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воробьева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorobyeva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Анатольевна Воробьёва, научный сотрудник, кандидат биологических наук, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Elena A. Vorobyeva, Cand. Sci. (Biol.), Researcher, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">vaa-vea-@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8109-5977</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пискарев</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Piskarev</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Валерьевич Пискарёв, кандидат медицинских наук, младший научный сотрудник, отдел по изучению пограничной психической патологии и психосоматических расстройств</p><p>Москва</p></bio><bio xml:lang="en"><p>Mikhail V. Piskarev, Cand. Sci. (Med.), Junior Researcher, Department for Studying of Borderline Mental Pathology and Psychosomatic Disorders</p><p>Moscow</p></bio><email xlink:type="simple">piskarev-mv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7744-533X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурбаева</surname><given-names>Г. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Burbaeva</surname><given-names>G. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гульнур Шингожиевна Бурбаева, доктор биологических наук, профессор, главный научный сотрудник, лаборатория нейрохимии</p><p>Москва</p></bio><bio xml:lang="en"><p>Gulnur Sh. Burbaeva, Professor, Dr. Sci. (Biol.), Chief Researcher, Neurochemistry Laboratory</p><p>Moscow</p></bio><email xlink:type="simple">gburb@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр психического здоровья»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBSI Mental Health Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>08</day><month>01</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><fpage>29</fpage><lpage>37</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Савушкина О.К., Бокша И.С., Прохорова Т.А., Терешкина Е.Б., Воробьева Е.А., Пискарев М.В., Бурбаева Г.Ш., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Савушкина О.К., Бокша И.С., Прохорова Т.А., Терешкина Е.Б., Воробьева Е.А., Пискарев М.В., Бурбаева Г.Ш.</copyright-holder><copyright-holder xml:lang="en">Savushkina O.K., Boksha I.S., Prokhorova T.A., Tereshkina E.B., Vorobyeva E.A., Piskarev M.V., Burbaeva G.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.journalpsychiatry.com/jour/article/view/1246">https://www.journalpsychiatry.com/jour/article/view/1246</self-uri><abstract><p>Обоснование: окислительный стресс и глутатионовая антиоксидантная система — это патогенетические звенья, задействованные как в патогенезе шизофрении и расстройств шизофренического спектра (РШС), так и в развитии кататонии, часто встречающейся при шизофрении и РШС. Цель: стратификация пациентов с приступами периодической кататонии, формирующимися в клиническом пространстве шизофрении и РШС, на основании активности тромбоцитарных и эритроцитарных ферментов глутатионовой системы и сравнительный анализ активности этих ферментов у пациентов с разными формами приступов. Пациенты и методы: в исследование включены пациенты с шизофренией и РШС с гипо-, пара- и мультикинетической формами приступов периодической кататонии (соответственно n = 13, 11 и 15) и контрольная группа здоровых лиц (n = 21). В экстрактах тромбоцитов и эритроцитов крови пациентов и контрольной группы определены активности глутатионредуктазы и глутатион-S-трансферазы спектрофотометрическими кинетическими методами. Результаты: при кластеризации пациентов по четырем биохимическим признакам получены два кластера с активностью ферментов, значимо отличающейся от уровней в контрольной группе, и значимо неравномерным распределением пациентов с разными формами приступов кататонии: для больных с гипо- и паракинетической кататонией χ2 = 20,3, р &lt; 0,0001 (с поправкой Йетса); для больных с пара- и мультикинетической кататонией χ2 = 16,9, р &lt; 0,0001 (с поправкой Йетса). Выводы: для пациентов с разными формами приступов кататонии характерны различные паттерны изменений уровней активности изученных ферментов относительно контрольных диапазонов. Определение активности глутатионовых ферментов в крови пациентов с РШС информативно для углубленной стратификации таких пациентов, в том числе в дифференцировании форм кататонии при РШС, и эти биохимические параметры могут служить дополнением к клиническим характеристикам для уточнения формы приступа кататонии.</p></abstract><trans-abstract xml:lang="en"><p>Background: oxidative stress and glutathione antioxidant system are pathogenetic chains involved both in the pathogenesis of schizophrenia and schizophrenia spectrum disorders (SSD), and in the development of catatonia, which is often found in schizophrenia and SSD. The aim: is to stratify patients with periodic catatonia in schizophrenia and SSD, based on the activity of platelet and erythrocyte enzymes of glutathione system and to comparatively analyze the activity of the enzymes in patients with different forms of catatonia. Patients and Methods: patients with schizophrenia and SSD with hypo-; para- and multi-kinetic forms of periodic catatonia (n = 13, 11 and 15, respectively) and mentally healthy persons of control group (n = 21) were included into the study. Activities of glutathione reductase and glutathione-S-transferase were determined by spectrophotometric kinetic methods in extracts of platelets and erythrocytes from the blood of patients and the control group. Results: when clustering patients by these four biochemical characteristics, two clusters were obtained with the enzymatic activities significantly differed from the levels in the control group, and significantly uneven distribution of patients with different forms of catatonia was observed between the clusters: χ2 = 20.3, p &lt; 0.0001 (with Yates’ correction) for patients with hypo- and para-kinetic catatonia; χ2 = 16.9, p &lt; 0.0001 (with Yates’ correction) for patients with para- and multi-kinetic catatonia. Conclusions: patients with different forms of catatonia are characterized by different patterns of changes in the activity levels of the studied enzymes relatively to the control ranges. Determining the activity of glutathione enzymes in the blood of patients with SSD is informative for in-depth stratification of such patients, including in differentiating the forms of catatonia in SSD, and these biochemical parameters can serve as an addition to clinical characteristics to clarify the form of periodic catatonia.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>расстройства шизофренического спектра</kwd><kwd>шизофрения</kwd><kwd>периодическая кататония</kwd><kwd>глутатионредуктаза</kwd><kwd>глутатион-S-трансфераза</kwd><kwd>тромбоциты</kwd><kwd>эритроциты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>schizophrenia spectrum disorders</kwd><kwd>schizophrenia</kwd><kwd>periodic catatonia</kwd><kwd>glutathione reductase</kwd><kwd>glutathione S-transferase</kwd><kwd>platelets</kwd><kwd>red blood cells</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR. Smirnova LP. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021:1-37. doi: 10.1155/2021/8881770</mixed-citation><mixed-citation xml:lang="en">Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR. Smirnova LP. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021:1-37. doi: 10.1155/2021/8881770</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Heckers S, Walther S. Catatonia. N Engl J Med. 2023 Nov 9;389(19):1797-1802. doi: 10.1056/NEJMra2116304. PMID: 37937779.</mixed-citation><mixed-citation xml:lang="en">Heckers S, Walther S. Catatonia. N Engl J Med. 2023 Nov 9;389(19):1797-1802. doi: 10.1056/NEJMra2116304. PMID: 37937779.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, Monaco F, Carvalho AF, Stubbs B, Veronese N, Correll CU. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophr Bull. 2018;44(5):1133-1150. doi: 10.1093/schbul/sbx157</mixed-citation><mixed-citation xml:lang="en">Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, Monaco F, Carvalho AF, Stubbs B, Veronese N, Correll CU. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophr Bull. 2018;44(5):1133-1150. doi: 10.1093/schbul/sbx157</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Пискарёв МВ, Лобанова ВМ, Румянцева ЕБ. Кататония в структуре аффективных и шизоаффективных расстройств послеродового периода. Психиатрия. 2023;21(3):54-63.</mixed-citation><mixed-citation xml:lang="en">Piskarev MV, Lobanova VM, Rumyantseva EB. Catatonia in the Structure of Affective and Schizoaffective Disorders of the Postpartum Period. Psychiatry (Moscow) (Psikhiatriya). 2023:21(3):54-63. (In Russ.). doi: 10.30629/2618-6667-2023-21-3-54-63</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Пискарев МВ, Лобанова ВМ, Ильина НА. Периодическая кататония при расстройствах шизофренического спектра. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):98-106.</mixed-citation><mixed-citation xml:lang="en">Piskarev MV, Lobanova VM, Ilyina NA. Periodic catatonia in schizophrenia spectrum disorders S.S. Korsakov Journal of Neurology and Psychiatry. 2023; 123(8):98-106. (In Russ.). doi: 10.17116/jnevro2023123081986. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Walther S, Stegmayer K, Wilson JE, Heckers S. Structure and neural mechanisms of catatonia. Lancet Psychiatry. 2019;6(7):610-619. doi: 10.1016/S2215-0366(18)30474-7</mixed-citation><mixed-citation xml:lang="en">Walther S, Stegmayer K, Wilson JE, Heckers S. Structure and neural mechanisms of catatonia. Lancet Psychiatry. 2019;6(7):610-619. doi: 10.1016/S2215-0366(18)30474-7</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ariza-Salamanca DF, Corrales-Hernández MG, Pachón-Londoño MJ, Hernández-Duarte I. Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence. Front Mol Neurosci. 2022;15:993671. doi: 10.3389/fnmol.2022.993671</mixed-citation><mixed-citation xml:lang="en">Ariza-Salamanca DF, Corrales-Hernández MG, Pachón-Londoño MJ, Hernández-Duarte I. Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence. Front Mol Neurosci. 2022;15:993671. doi: 10.3389/fnmol.2022.993671</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta A, Kumar A, Kulkarni SK. Targeting oxidative stress, mitochondrial dysfunction and neuroin-flammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):974-981. doi: 10.1016/j.pnpbp.2011.01.017</mixed-citation><mixed-citation xml:lang="en">Gupta A, Kumar A, Kulkarni SK. Targeting oxidative stress, mitochondrial dysfunction and neuroin-flammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):974-981. doi: 10.1016/j.pnpbp.2011.01.017</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Савушкина ОК, Бокша ИС, Прохорова ТА, Терешкина ЕБ, Бурминский ДС, Морозова МА, Воробьева ЕА, Бурбаева ГШ. Активность эритроцитарных и тромбоцитарных глутатионредуктазы и глутатион-S-трансферазы при параноидной шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(11):77-81.</mixed-citation><mixed-citation xml:lang="en">Savushkina OK, Boksha IS, Prokhorova TA, Tereshkina EB, Burminskii DS, Morozova MA, Vorobeva EA, Burbaeva GSh. The activity of erythrocyte and platelet glutathione reductase and glutathione-S-transferase in paranoid schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(11):77-81. (In Russ.). doi: 10.17116/jnevro201811811177</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Терешкина ЕБ, Савушкина ОК, Бокша ИС, Прохорова ТА, Воробьева ЕА, Омельченко МА, Помыткин АН, Каледа ВГ, Бурбаева ГШ. Глутатионредуктаза и глутатион-S-трансфераза в форменных элементах крови при шизофрении и расстройствах шизофренического спектра. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2):61-65.</mixed-citation><mixed-citation xml:lang="en">Tereshkina EB, Savushkina OK, Boksha IS, Prokhorova TA, Vorobeva EA, Omel’chenko MA, Pomytkin AN, Kaleda VG, Burbaeva GSh. Glutathione reductase and glutathione-S-transferase in blood cells in schizophrenia and schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119(2):61-65. (In Russ.). doi: 10.17116/jnevro201911902161</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Прохорова ТА, Терешкина ЕБ, Савушкина ОК, Бокша ИС, Воробьева ЕА, Омельченко МА, Помыткин АН, Каледа ВГ, Бурбаева ГШ. Активность ферментов глутатионового обмена в форменных элементах крови у пациентов с высоким риском манифестации эндогенных психозов и больных с первым психотическим приступом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119(4):47-54.</mixed-citation><mixed-citation xml:lang="en">Prokhorova TA, Tereshkina EB, Savushkina OK, Boksha IS, Vorobeva EA, Omel’chenko MA, Pomytkin AN, Kaleda VG, Burbaeva GSh. The activity of enzymes of glutathione metabolism in blood cells of patients with a high risk of manifestation of endogenous psychoses and patients with the first psychotic episode. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):47-54. (In Russ.). doi: 10.17116/jnevro201911904147</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Савушкина ОК, Бокша ИС, Омельченко МА, Терешкина ЕБ, Прохорова ТА, Воробьева ЕА, Бурбаева ГШ. Активность ферментов глутаматного, энергетического и глутатионового обмена при первых юношеских депрессиях с аттенуированными симптомами шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(8):136-144.</mixed-citation><mixed-citation xml:lang="en">Savushkina OK, Boksha IS, Omelchenko MA, Tereshkina EB, Prokhorova TA, Vorobyeva EA, Burbaeva GSh. Activity of enzymes of glutamate, energy and glutathione metabolism in the first juvenile depression with attenuated symptoms of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122(8):136-144. (In Russ.). doi: 10.17116/jnevro2022122081136</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen R-A, Huang T-L. Periodic catatonia with longterm treatment: a case report. BMC Psychiatry. 2017;17(1):337. doi: 10.1186/s12888-017-1497-6.</mixed-citation><mixed-citation xml:lang="en">Chen R-A, Huang T-L. Periodic catatonia with longterm treatment: a case report. BMC Psychiatry. 2017;17(1):337. doi: 10.1186/s12888-017-1497-6</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Masselli E, Pozzi G, Vaccarezza M, Mirandola P, Galli D, Vitale M, Carubbi C, Gobbi G. ROS in Platelet Biology: Functional Aspects and Methodological Insights. Int J Mol Sci. 202021(14):4866. doi: 10.3390/ijms21144866</mixed-citation><mixed-citation xml:lang="en">Masselli E, Pozzi G, Vaccarezza M, Mirandola P, Galli D, Vitale M, Carubbi C, Gobbi G. ROS in Platelet Biology: Functional Aspects and Methodological Insights. Int J Mol Sci. 202021(14):4866. doi: 10.3390/ijms21144866 15. Langbein K, Hesse J, Gussew A, Milleit B, Lavoie S, Amminger GP, Gaser C, Wagner G, Reichenbach JR, Hipler UC, Winter D, Smesny S. Disturbed glutathione antioxidative defense is associated with structurabrain changes in neuroleptic-naïve first-episode psychosis patients. Prostaglandins Leukot Essent Fatty Acids. 2018;136:103-110. doi: 10.1016/j.plefa.2017.10.005</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Langbein K, Hesse J, Gussew A, Milleit B, Lavoie S, Amminger GP, Gaser C, Wagner G, Reichenbach JR, Hipler UC, Winter D, Smesny S. Disturbed glutathione antioxidative defense is associated with structurabrain changes in neuroleptic-naïve first-episode psychosis patients. Prostaglandins Leukot Essent Fatty Acids. 2018;136:103-110. doi: 10.1016/j.plefa.2017.10.005</mixed-citation><mixed-citation xml:lang="en">Viinamäki H, Marin E, Kuha S. Activities of Glutathione Reductase, S-Transferase, and Peroxidase in Schizophrenic Patients. Nordic Journal of Psychiatry. 1994;48(4):247-250. doi:10.3109/08039489409078144</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Viinamäki H, Marin E, Kuha S. Activities of Glutathione Reductase, S-Transferase, and Peroxidase in Schizophrenic Patients. Nordic Journal of Psychiatry. 1994;48(4):247-250. doi:10.3109/08039489409078144</mixed-citation><mixed-citation xml:lang="en">Shhigoreva JuG, Smirnova LP. Vlijanie tipichnyh i atipichnyh nejroleptikov na aktivnosti antioksidantnoj sistemy u bol’nyh shizofreniej. Siberian Herald of Psychiatry and Addiction Psychiatry. Supplement: Actual problems of psychiatry and narcology. 2011;15:167-169. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Щигорева ЮГ, Смирнова ЛП. Влияние типичных и атипичных нейролептиков на активности антиоксидантной системы у больных шизофренией. Сибирский вестник психиатрии и наркологии. Приложение: Актуальные вопросы психиатрии и наркологии. 2011;15:167-169.</mixed-citation><mixed-citation xml:lang="en">Miljević Č, Nikolić-Kokić A, Saičić ZS, Milosavljević M, Blagojević D, Toševski DL, Jones D R, Spasić MB. Correlation analysis confirms differences in antioxidant defense in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication. Psychiatry Res. 2010;178(1):68-72. doi: 10.1016/j.psychres.2008.10.038</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Miljević Č, Nikolić-Kokić A, Saičić ZS, Milosavljević M, Blagojević D, Toševski DL, Jones D R, Spasić MB. Correlation analysis confirms differences in antioxidant defense in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication. Psychiatry Res. 2010;178(1):68-72. doi: 10.1016/j.psychres.2008.10.038</mixed-citation><mixed-citation xml:lang="en">Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, Elsalhy M, Kuromiya M, Kurose S, Masuda F, Morita S, Ogyu K, Plitman E, Wada M, Miyazaki T, Graff-Guerrero A, Mimura M, Nakajima S. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. J Psychopharmacol. 2019;33(10):1199-1214. doi: 10.1177/0269881119845820.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, Elsalhy M, Kuromiya M, Kurose S, Masuda F, Morita S, Ogyu K, Plitman E, Wada M, Miyazaki T, Graff-Guerrero A, Mimura M, Nakajima S. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. J Psychopharmacol. 2019;33(10):1199-1214. doi: 10.1177/0269881119845820.</mixed-citation><mixed-citation xml:lang="en">Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, Elsalhy M, Kuromiya M, Kurose S, Masuda F, Morita S, Ogyu K, Plitman E, Wada M, Miyazaki T, Graff-Guerrero A, Mimura M, Nakajima S. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. J Psychopharmacol. 2019;33(10):1199-1214. doi: 10.1177/0269881119845820.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
